

Special Issue

The Development of Effective Therapy Targeting the Microenvironment of Cancer

Message from the Guest Editors

For many years, cancer medications have primarily targeted the inhibition of cancer cell growth. However, over the past 20 years, the mechanisms that form the tumor microenvironment through interactions with the stromal cells surrounding cancer cells have been elucidated. These cancer stromal cells are involved in the proliferation, invasion, and metastasis of cancer cells, even though they are normal cells. Therefore, therapeutic approaches targeting the tumor microenvironment have recently attracted much attention. In this Special Issue, we are seeking papers on innovative therapies targeting the tumor microenvironment. Proposals for any type of therapy, e.g., chemotherapy, antibody therapy, radiation therapy, etc., will be accepted. However, it is preferable that the results be proven to be effective at the animal level, rather than in a culture system.

Guest Editors

Prof. Dr. Moriaki Kusakabe

Graduate School of Agricultural and Life Science, University of Tokyo, Tokyo 113-8657, Japan

Dr. Sasagu Kurozumi

Department of Breast Surgery, International University of Health and Welfare, Narita 286-8686, Chiba, Japan

Deadline for manuscript submissions

closed (25 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/119126

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)